Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Jennifer Kelly Shepphird, PhD
Advertisement
Articles by Jennifer Kelly Shepphird, PhD
Advertisement
Latest Updated Articles
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma CollaborationPublished: January 9th 2015 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years
2
Patients Treated With AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy AB-1003 Free of Serious Adverse Events at Up to 52 Weeks
3
CGTLive®’s Weekly Rewind – October 17, 2025
4
